Maloney A - Search Results

1

Optimal adaptive design in clinical drug development: a simulation example.

Maloney A, Karlsson MO, Simonsson US. Maloney A, et al. J Clin Pharmacol. 2007 Oct;47(10):1231-43. doi: 10.1177/0091270007308033. J Clin Pharmacol. 2007. PMID: 17906158

2

An example of optimal phase II design for exposure response modelling.

Maloney A, Schaddelee M, Freijer J, Krauwinkel W, van Gelderen M, Jacqmin P, Simonsson US. Maloney A, et al. J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):475-91. doi: 10.1007/s10928-010-9168-y. Epub 2010 Sep 25. J Pharmacokinet Pharmacodyn. 2010. PMID: 20872056

3

D optimal designs for three Poisson dose-response models.

Maloney A, Simonsson US, Schaddelee M. Maloney A, et al. J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):201-11. doi: 10.1007/s10928-013-9300-x. Epub 2013 Feb 19. J Pharmacokinet Pharmacodyn. 2013. PMID: 23420229

4

Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Plan EL, Maloney A, Mentré F, Karlsson MO, Bertrand J. Plan EL, et al. Among authors: maloney a. AAPS J. 2012 Sep;14(3):420-32. doi: 10.1208/s12248-012-9349-2. Epub 2012 Apr 14. AAPS J. 2012. PMID: 22528503 Free PMC article.

5

Performance in population models for count data, part I: maximum likelihood approximations.

Plan EL, Maloney A, Trocóniz IF, Karlsson MO. Plan EL, et al. Among authors: maloney a. J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):353-66. doi: 10.1007/s10928-009-9126-8. Epub 2009 Aug 4. J Pharmacokinet Pharmacodyn. 2009. PMID: 19653080

6

A New Paradigm. "Learn - Learn More"; Dose-Exposure-Response at the Center of Drug Development and Regulatory Approval.

Maloney A. Maloney A. Clin Pharmacol Ther. 2017 Dec;102(6):942-950. doi: 10.1002/cpt.710. Epub 2017 May 30. Clin Pharmacol Ther. 2017. PMID: 28419437 Review.

7

A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.

Maloney A, Rosenstock J, Fonseca V. Maloney A, et al. Clin Pharmacol Ther. 2019 May;105(5):1213-1223. doi: 10.1002/cpt.1307. Epub 2019 Jan 13. Clin Pharmacol Ther. 2019. PMID: 30457671

8

Personalized Dosing = Approved Wide Dose Ranges + Dose Titration.

Maloney A. Maloney A. Clin Pharmacol Ther. 2021 Mar;109(3):566-567. doi: 10.1002/cpt.1997. Epub 2020 Aug 30. Clin Pharmacol Ther. 2021. PMID: 32864737 No abstract available.

9

The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.

Lötvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. Lötvall J, et al. Among authors: maloney a. J Allergy Clin Immunol. 2001 Nov;108(5):726-31. doi: 10.1067/mai.2001.119152. J Allergy Clin Immunol. 2001. PMID: 11692096 Clinical Trial.

10

Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. de Greef R, et al. Among authors: maloney a. AAPS J. 2011 Mar;13(1):121-30. doi: 10.1208/s12248-010-9247-4. Epub 2010 Dec 24. AAPS J. 2011. PMID: 21184291 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

214 results

Search Page